Rethinking Oncology Development: Master Protocols May Shorten Time To Approval
This article was originally published in RPM Report
Master protocols that allow for the simultaneous study of multiple agents will shave more time off in the clinic than one-off studies in small groups of patients, FDA’s Janet Woodcock predicted. The current timeframes in oncology development are “unacceptable,” and can be shortened, she said, by “doing things differently.”
You may also be interested in...
Master Protocols Are Both Welcome And Inevitable – US FDA's Woodcock
Center for Drug Evaluation and Research Director Janet Woodcock continues to promote innovation in clinical trial design with a review of master protocols in the New England Journal of Medicine.
Genentech Wants Other Firms' Compounds For Mass Pediatric Cancer Screening
Master protocol for Phase I/II screening trial could make development more efficient, but concerns about regulatory obligations, lack of registrational intent and infrastructure complexity – as well as firms' willingness to share – may be hurdles to participation.
I-SPY 2 Helping To Normalize Adaptive Trial Designs
Publication in NEJM of results from Phase II of master protocol study of breast cancer combinations also helps build support for Bayesian statistics.